Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ossotide
- Development stage
- Unknown
- Lead developer
- Jiangshi Pharma
- Modality
- Peptides
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
**Ossotide** is an animal bone-derived peptide extract medicine marketed in China in multiple dosage forms, including bone peptide injection and tablets. Heilongjiang Jiangshi Pharmaceutical markets ossotide products, including the injection brand Xiruo and ossotide tablets. The extract contains bone-metabolism-related peptide material; product information describes proposed effects of regulating bone metabolism, stimulating osteoblast proliferation, promoting new bone formation, and supporting calcium and phosphorus deposition. It is used for bone and joint disorders, including fracture healing, osteoarthritis, and rheumatic or rheumatoid arthritis. The precise molecular constituents and direct pharmacological targets are not well defined.
- Brand names
- Xiruo
- Other names
- 骨肽bone peptide
Beyond the preview
Go deeper on ossotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ossotide.